白斑治療薬の2030年までの市場予測

Vitiligo Treatment Market Forecast till 2030

白斑治療市場調査レポート 2030年までの予測市場の概要白斑治療市場は、調査期間中に6.20%のCAGRを記録すると予測されています。白斑は、メラノサイトと呼ばれる皮膚の色彩伝達細胞の故障や死滅によっても... もっと見る

出版社	出版年月	電子版価格	ページ数	言語
Market Research Future マーケットリサーチフューチャー (MRFR)	2023年3月7日	US$7,250 ライセンス・価格情報注文方法はこちら	122	英語

目次
図表リスト

サマリー

白斑治療市場調査レポート 2030年までの予測

市場の概要
白斑治療市場は、調査期間中に6.20%のCAGRを記録すると予測されています。白斑は、メラノサイトと呼ばれる皮膚の色彩伝達細胞の故障や死滅によってもたらされる皮膚の色素脱失によって描かれる、持続的な皮膚科学的問題です。そのため、皮膚に白い斑点が現れます。この状態が続くと、より広い範囲の肌の色が失われていきます。治療により、皮膚の外観がさらに改善されるかもしれませんが、病気は治りません。世界の白斑治療市場を牽引する主な要因は、センスの良い魅力と心遣いの重要性の高まりと、白斑患者の一般性の上昇である。
最近では、様々なスタイル治療に対する消費者の意識の高まり、一人当たりの給与の拡大、コンピュータ化されたステージの受信などから、消費者の間で優れた認知度が大きく上昇しています。グローバル・ソサイエティ・オブ・スタイリッシュ・プラスチック・メディカル・プロシージャ（ISAPS）によると、2015年から2019年の間のどこかで、全体の完全非手術に27.3％の発展があった。さらに、American Culture of Plastic Specialists（ASPS）が示すように、過失的に侵入する味覚システムの数量は、2000年から2017年の間に約200％の拡大を見た。その上、2018年には約1590万件のネグリジブル・オブラスティブ修復法が作用し、これは2017年との対比で2％上昇した。その後、老年人口が増加していることが、さらに、無視できるほど鈍感な修復方法への関心を高めています。
セグメントの概要
タイプ別では、白斑治療市場は分節性白斑と非分節性白斑に分類されます。治療タイプ別では、市場は手術、治療、薬物療法に分類されます。
エンドユーザー産業別では、市場は外来診療所、病院、その他に分類されます。
地域別分析
北米は2021年に世界の白斑治療市場を支配し、返済運動の存在と、同様に地域の市場開発に追加される味わい深い魅力の発展する意義に起因しています。
Diary of the European Foundation of Dermatology and Venereology (JEADV)に掲載された記事によると、オンラインポピュラスベースの研究では、ヨーロッパにおける白斑の一般性は1.3%であることが示された。また、この地域では、白斑治療戦略の機械的な進歩が進んでおり、その理由は、多くの患者が苦しんでいるためです。
アジア太平洋地域の白斑治療市場は、革新的な作業演習の数の拡大と白斑治療の選択肢に対する関心の発展によって牽引されています。例えば、Indian Dermatology Online Diary (IDOJ)が示すように、200人の白斑患者を対象に横断的なレビューが行われ、16.5%の人が分節性白斑であり、83.5%が非分節性白斑であると表現されている。また、この地域における買収、共同作業、行政による承認、利益供与など、さまざまな公的機関や秘密団体による推進活動が活発化していることも、市場の発展に寄与しています。
主要プレイヤー
Incyte社（米国）、Koninklijke Philips N.V.（オランダ）、Bausch Health Companies Inc.（カナダ）、Reddy's Laboratories Ltd.(インド)、STRATA Skin Sciences(米国)、Clinuvel Pharmaceuticals Ltd(オーストラリア)、Roivant Sciences Ltd.(Switzerland)(スイス)、ISSAR Pharmaceuticals Pvt.Ltd. (インド)、Kernel Medical Ltd. (インド)(インド)、Kernel Medical Equipment Co., LTD.(中国)、LightSource(米国)があります。
COVID 19の影響
私たちは、COVID-19の流行があらゆる分野の様々な業界や業種に与える影響を継続的に追跡しています。当社の調査レポートでは、COVID-19の産業への影響による減少や上昇を理解するのに役立ちます。また、関心のある市場の需要と供給のギャップを特定するのに役立ちます。さらに、このレポートは、分析、改正された政府規制、および他の多くの有用な洞察であなたを支援します。

ページTOPに戻る

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

1.1 OVERVIEW

1.1.1 MARKET SYNOPSIS

2 MARKET INTRODUCTION

2.1 DEFINITION

2.2 SCOPE OF THE STUDY

2.3 RESEARCH OBJECTIVE

2.4 LIST OF ASSUMPTIONS

3 RESEARCH METHODOLOGY

3.1 OVERVIEW

3.2 DATA MINING

3.3 SECONDARY RESEARCH

3.4 PRIMARY RESEARCH

3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS

3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS

3.5 FORECASTING TECHNIQUES

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION

3.6.1 BOTTOM-UP APPROACH

3.6.2 TOP-DOWN APPROACH

3.7 DATA TRIANGULATION

3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW

4.2 DRIVERS

4.2.1 GROWING IMPORTANCE OF THE AESTHETIC APPEAL AND AWARENESS

4.2.2 INCREASING PREVALENCE OF VITLIGO

4.3 RESTRAINTS

4.3.1 LACK OF TRAINED PROFESSIONALS

4.4 OPPORTUNITIES

4.4.1 RISING NUMBER OF CLINICAL TRIALS

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS

5.1.1 R&D

5.1.2 MANUFACTURING

5.1.3 DISTRIBUTION & SALES

5.1.4 POST-SALES MONITORING

5.2 PORTER'S FIVE FORCES MODEL

5.2.1 THREAT OF NEW ENTRANTS

5.2.2 BARGAINING POWER OF SUPPLIERS

5.2.3 THREAT OF SUBSTITUTES

5.2.4 BARGAINING POWER OF BUYERS

5.2.5 INTENSITY OF RIVALRY

5.3 IMPACT OF COVID-19 ON THE VITILIGO TREATMENT MARKET

5.3.1 IMPACT ON SUPPLY CHAIN

5.3.2 IMPACT ON REGION

5.3.3 IMPACT ON DEMAND AND SUPPLY

6 GLOBAL VITILIGO TREATMENT MARKET, BY TYPE

6.1 OVERVIEW

6.2 SEGMENTAL VITILIGO

6.3 NON-SEGMENTAL VITILIGO

7 GLOBAL VITILIGO TREATMENT MARKET, BY TREATMENT TYPE

7.1 OVERVIEW

7.2 THERAPY

7.2.1 DEPIGMENTATION

7.2.2 LIGHT

7.3 SURGERY

7.3.1 SKIN GRAFTING

7.3.2 BLISTER GRAFTING

7.3.3 MICRO-PIGMENTATION

7.4 MEDICATION

7.4.1 TOPICAL CORTICOSTEROIDS

7.4.2 IMMUNOSUPPRESSIVE

8 GLOBAL VITILIGO TREATMENT MARKET, BY END USER

8.1 OVERVIEW

8.2 HOSPITALS

8.3 AMBULATORY CLINICS

8.4 OTHERS

9 GLOBAL VITILIGO TREATMENT MARKET, BY REGION

9.1 OVERVIEW

9.2 NORTH AMERICA

9.2.1 US

9.2.2 CANADA

9.3 EUROPE

9.3.1 GERMANY

9.3.2 FRANCE

9.3.3 UK

9.3.4 ITALY

9.3.5 SPAIN

9.3.6 REST OF EUROPE

9.4 ASIA-PACIFIC

9.4.1 CHINA

9.4.2 JAPAN

9.4.3 INDIA

9.4.4 SOUTH KOREA

9.4.5 AUSTRALIA

9.4.6 REST OF ASIA-PACIFIC

9.5 REST OF THE WORLD

9.5.1 MIDDLE EAST

9.5.2 AFRICA

9.5.3 LATIN AMERICA

10 COMPETITIVE LANDSCAPE

10.1 OVERVIEW

10.2 COMPETITIVE BENCHMARKING

10.3 MAJOR GROWTH STRATEGY IN VITILIGO TREATMENT MARKET

10.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN VITILIGO TREATMENT MARKET

10.5 KEY DEVELOPMENT ANALYSIS

10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES

10.6.1 PRODUCT APPROVALS/PRODUCT LAUNCHES/DRUG PIPELINE

10.6.2 MERGERS & ACQUISITIONS

10.7 MAJOR PLAYERS SALES ANALYSIS

10.7.1 SALES & OPERATING INCOME, 2021

10.7.2 MAJOR PLAYERS R&D ANALYSIS, 2021

11 COMPANY PROFILE

11.1 INCYTE

11.1.1 COMPANY OVERVIEW

11.1.2 FINANCIAL OVERVIEW

11.1.3 PRODUCTS OFFERED

11.1.4 KEY DEVELOPMENTS

11.1.5 SWOT ANALYSIS

11.1.6 KEY STRATEGIES

11.2 BAUSCH HEALTH COMPANIES INC.

11.2.1 COMPANY OVERVIEW

11.2.2 FINANCIAL OVERVIEW

11.2.3 PRODUCTS OFFERED

11.2.4 KEY DEVELOPMENTS

11.2.5 SWOT ANALYSIS

11.2.6 KEY STRATEGIES

11.3 KONINKLIJKE PHILIPS N.V.

11.3.1 COMPANY OVERVIEW

11.3.2 FINANCIAL OVERVIEW

11.3.3 PRODUCTS OFFERED

11.3.4 KEY DEVELOPMENTS

11.3.5 SWOT ANALYSIS

11.3.6 KEY STRATEGIES

11.4 DR. REDDY'S LABORATORIES LTD.

11.4.1 COMPANY OVERVIEW

11.4.2 FINANCIAL OVERVIEW

11.4.3 PRODUCTS OFFERED

11.4.4 KEY DEVELOPMENTS

11.4.5 SWOT ANALYSIS

11.4.6 KEY STRATEGIES

11.5 STRATA SKIN SCIENCES

11.5.1 COMPANY OVERVIEW

11.5.2 FINANCIAL OVERVIEW

11.5.3 PRODUCTS OFFERED

11.5.4 KEY DEVELOPMENTS

11.5.5 KEY STRATEGIES

11.6 CLINUVEL PHARMACEUTICALS LTD

11.6.1 COMPANY OVERVIEW

11.6.2 FINANCIAL OVERVIEW

11.6.3 PRODUCTS OFFERED

11.6.4 KEY DEVELOPMENTS

11.6.5 SWOT ANALYSIS

11.6.6 KEY STRATEGIES

11.7 ISSAR PHARMACEUTICALS PVT. LTD.

11.7.1 COMPANY OVERVIEW

11.7.2 FINANCIAL ANALYSIS

11.7.3 PRODUCTS OFFERED

11.7.4 KEY DEVELOPMENTS

11.7.5 KEY STRATEGIES

11.8 KERNEL MEDICAL EQUIPMENT CO., LTD.

11.8.1 COMPANY OVERVIEWS

11.8.2 FINANCIAL OVERVIEW

11.8.3 PRODUCTS OFFERED

11.8.4 KEY DEVELOPMENTS

11.8.5 KEY STRATEGIES

11.9 LIGHTSOURCES

11.9.1 COMPANY OVERVIEW

11.9.2 FINANCIAL ANALYSIS

11.9.3 PRODUCTS OFFERED

11.9.4 KEY DEVELOPMENTS

11.9.5 KEY STRATEGIES

11.10 ROIVANT SCIENCES LTD.

11.10.1 COMPANY OVERVIEW

11.10.2 FINANCIAL ANALYSIS

11.10.3 PRODUCTS OFFERED

11.10.4 KEY DEVELOPMENTS

11.10.5 PRODUCTS OFFERED

11.10.6 KEY STRATEGIES

12 APPENDIX

12.1 REFERENCES

12.2 RELATED REPORTS

ページTOPに戻る

図表リスト

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS

TABLE 2 GLOBAL VITILIGO TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 3 GLOBAL VITILIGO TREATMENT MARKET, FOR SEGMENTAL VITILIGO, BY REGION, 2018–2030 (USD MILLION)

TABLE 4 GLOBAL VITILIGO TREATMENT MARKET, FOR NON-SEGMENTAL VITILIGO, BY REGION, 2018–2030 (USD MILLION)

TABLE 5 GLOBAL VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018–2030 (USD MILLION)

TABLE 6 GLOBAL VITILIGO TREATMENT MARKET, FOR THERAPY, BY REGION, 2018–2030 (USD MILLION)

TABLE 7 GLOBAL VITILIGO TREATMENT MARKET, FOR DEPIGMENTATION, BY REGION, 2018–2030 (USD MILLION)

TABLE 8 GLOBAL VITILIGO TREATMENT MARKET, FOR LIGHT, BY REGION, 2018–2030 (USD MILLION)

TABLE 9 GLOBAL VITILIGO TREATMENT MARKET, FOR SURGERY, BY REGION, 2018–2030 (USD MILLION)

TABLE 10 GLOBAL VITILIGO TREATMENT MARKET, FOR SKIN GRAFTING, BY REGION, 2018–2030 (USD MILLION)

TABLE 11 GLOBAL VITILIGO TREATMENT MARKET, FOR BLISTER GRAFTING, BY REGION, 2018–2030 (USD MILLION)

TABLE 12 GLOBAL VITILIGO TREATMENT MARKET, FOR MICRO-PIGMENTATION, BY REGION, 2018–2030 (USD MILLION)

TABLE 13 GLOBAL VITILIGO TREATMENT MARKET, FOR MEDICATION, BY REGION, 2018–2030 (USD MILLION)

TABLE 14 GLOBAL VITILIGO TREATMENT MARKET, FOR TOPICAL CORTICOSTEROIDS, BY REGION, 2018–2030 (USD MILLION)

TABLE 15 GLOBAL VITILIGO TREATMENT MARKET, FOR IMMUNOSUPPRESSIVE, BY REGION, 2018–2030 (USD MILLION)

TABLE 16 GLOBAL VITILIGO TREATMENT MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 17 GLOBAL VITILIGO TREATMENT MARKET, FOR HOSPITALS, BY REGION, 2018–2030 (USD MILLION)

TABLE 18 GLOBAL VITILIGO TREATMENT MARKET, FOR AMBULATORY CLINICS, BY REGION, 2018–2030 (USD MILLION)

TABLE 19 GLOBAL VITILIGO TREATMENT MARKET, FOR OTHERS, BY REGION, 2018–2030 (USD MILLION)

TABLE 20 GLOBAL: VITILIGO TREATMENT MARKET, BY REGION, 2018–2030 (USD MILLION)

TABLE 21 NORTH AMERICA: VITILIGO TREATMENT MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 22 NORTH AMERICA: VITILIGO TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 23 NORTH AMERICA: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018–2030 (USD MILLION)

TABLE 24 NORTH AMERICA: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 25 NORTH AMERICA: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 26 NORTH AMERICA: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018–2030 (USD MILLION)

TABLE 27 NORTH AMERICA: VITILIGO TREATMENT MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 28 US: VITILIGO TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 29 US: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018–2030 (USD MILLION)

TABLE 30 US: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 31 US: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 32 US: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018–2030 (USD MILLION)

TABLE 33 US: VITILIGO TREATMENT MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 34 CANADA: VITILIGO TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 35 CANADA: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018–2030 (USD MILLION)

TABLE 36 CANADA: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 37 CANADA: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 38 CANADA: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018–2030 (USD MILLION)

TABLE 39 CANADA: VITILIGO TREATMENT MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 40 EUROPE: VITILIGO TREATMENT MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 41 EUROPE: VITILIGO TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 42 EUROPE: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018–2030 (USD MILLION)

TABLE 43 EUROPE: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 44 EUROPE: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 45 EUROPE: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018–2030 (USD MILLION)

TABLE 46 EUROPE: VITILIGO TREATMENT MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 47 GERMANY: VITILIGO TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 48 GERMANY: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018–2030 (USD MILLION)

TABLE 49 GERMANY: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 50 GERMANY: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 51 GERMANY: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018–2030 (USD MILLION)

TABLE 52 GERMANY: VITILIGO TREATMENT MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 53 FRANCE: VITILIGO TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 54 FRANCE: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018–2030 (USD MILLION)

TABLE 55 FRANCE: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 56 FRANCE: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 57 FRANCE: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018–2030 (USD MILLION)

TABLE 58 FRANCE: VITILIGO TREATMENT MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 59 UK: VITILIGO TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 60 UK: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018–2030 (USD MILLION)

TABLE 61 UK: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 62 UK: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 63 UK: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018–2030 (USD MILLION)

TABLE 64 UK: VITILIGO TREATMENT MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 65 ITALY: VITILIGO TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 66 ITALY: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018–2030 (USD MILLION)

TABLE 67 ITALY: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 68 ITALY: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 69 ITALY: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018–2030 (USD MILLION)

TABLE 70 ITALY: VITILIGO TREATMENT MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 71 SPAIN: VITILIGO TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 72 SPAIN: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018–2030 (USD MILLION)

TABLE 73 SPAIN: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 74 SPAIN: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 75 SPAIN: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018–2030 (USD MILLION)

TABLE 76 SPAIN: VITILIGO TREATMENT MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 77 REST OF EUROPE: VITILIGO TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 78 REST OF EUROPE: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018–2030 (USD MILLION)

TABLE 79 REST OF EUROPE: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 80 REST OF EUROPE: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 81 REST OF EUROPE: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018–2030 (USD MILLION)

TABLE 82 REST OF EUROPE: VITILIGO TREATMENT MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 83 ASIA-PACIFIC: VITILIGO TREATMENT MARKET, BY COUNTRY, 2018-2030 (USD MILLION)

TABLE 84 ASIA-PACIFIC: VITILIGO TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)

TABLE 85 ASIA-PACIFIC: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018-2030 (USD MILLION)

TABLE 86 ASIA-PACIFIC: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)

TABLE 87 ASIA-PACIFIC: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018-2030 (USD MILLION)

TABLE 88 ASIA-PACIFIC: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018-2030 (USD MILLION)

TABLE 89 ASIA-PACIFIC: VITILIGO TREATMENT MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 90 CHINA: VITILIGO TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)

TABLE 91 CHINA: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018-2030 (USD MILLION)

TABLE 92 CHINA: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)

TABLE 93 CHINA: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018-2030 (USD MILLION)

TABLE 94 CHINA: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018-2030 (USD MILLION)

TABLE 95 CHINA: VITILIGO TREATMENT MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 96 JAPAN: VITILIGO TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)

TABLE 97 JAPAN: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018-2030 (USD MILLION)

TABLE 98 JAPAN: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)

TABLE 99 JAPAN: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018-2030 (USD MILLION)

TABLE 100 JAPAN: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018-2030 (USD MILLION)

TABLE 101 JAPAN: VITILIGO TREATMENT MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 102 INDIA: VITILIGO TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)

TABLE 103 INDIA: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018-2030 (USD MILLION)

TABLE 104 INDIA: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)

TABLE 105 INDIA: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018-2030 (USD MILLION)

TABLE 106 INDIA: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018-2030 (USD MILLION)

TABLE 107 INDIA: VITILIGO TREATMENT MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 108 SOUTH KOREA: VITILIGO TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)

TABLE 109 SOUTH KOREA: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018-2030 (USD MILLION)

TABLE 110 SOUTH KOREA: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)

TABLE 111 SOUTH KOREA: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018-2030 (USD MILLION)

TABLE 112 SOUTH KOREA: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018-2030 (USD MILLION)

TABLE 113 SOUTH KOREA: VITILIGO TREATMENT MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 114 AUSTRALIA: VITILIGO TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)

TABLE 115 AUSTRALIA: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018-2030 (USD MILLION)

TABLE 116 AUSTRALIA: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)

TABLE 117 AUSTRALIA: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018-2030 (USD MILLION)

TABLE 118 AUSTRALIA: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018-2030 (USD MILLION)

TABLE 119 AUSTRALIA: VITILIGO TREATMENT MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 120 REST OF ASIA-PACIFIC: VITILIGO TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)

TABLE 121 REST OF ASIA-PACIFIC: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018-2030 (USD MILLION)

TABLE 122 REST OF ASIA-PACIFIC: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)

TABLE 123 REST OF ASIA-PACIFIC: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018-2030 (USD MILLION)

TABLE 124 REST OF ASIA-PACIFIC: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018-2030 (USD MILLION)

TABLE 125 REST OF ASIA-PACIFIC: VITILIGO TREATMENT MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 126 REST OF THE WORLD: VITILIGO TREATMENT MARKET, BY COUNTRY, 2018-2030 (USD MILLION)

TABLE 127 REST OF THE WORLD: VITILIGO TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)

TABLE 128 REST OF THE WORLD: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018-2030 (USD MILLION)

TABLE 129 REST OF THE WORLD: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)

TABLE 130 REST OF THE WORLD: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018-2030 (USD MILLION)

TABLE 131 REST OF THE WORLD: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018-2030 (USD MILLION)

TABLE 132 REST OF THE WORLD: VITILIGO TREATMENT MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 133 MIDDLE EAST: VITILIGO TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)

TABLE 134 MIDDLE EAST: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018-2030 (USD MILLION)

TABLE 135 MIDDLE EAST: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)

TABLE 136 MIDDLE EAST: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018-2030 (USD MILLION)

TABLE 137 MIDDLE EAST: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018-2030 (USD MILLION)

TABLE 138 MIDDLE EAST: VITILIGO TREATMENT MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 139 AFRICA: VITILIGO TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)

TABLE 140 AFRICA: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018-2030 (USD MILLION)

TABLE 141 AFRICA: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)

TABLE 142 AFRICA: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018-2030 (USD MILLION)

TABLE 143 AFRICA: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018-2030 (USD MILLION)

TABLE 144 AFRICA: VITILIGO TREATMENT MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 145 LATIN AMERICA: VITILIGO TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)

TABLE 146 LATIN AMERICA: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018-2030 (USD MILLION)

TABLE 147 LATIN AMERICA: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)

TABLE 148 LATIN AMERICA: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018-2030 (USD MILLION)

TABLE 149 LATIN AMERICA: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018-2030 (USD MILLION)

TABLE 150 LATIN AMERICA: VITILIGO TREATMENT MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 151 MAJOR MANUFACTURERS IN VITILIGO TREATMENT MARKET

TABLE 152 MOST ACTIVE PLAYER IN VITILIGO TREATMENT MARKET

TABLE 153 PRODUCT APPROVALS/PRODUCT LAUNCHES/DRUG PIPELINE

TABLE 154 MERGERS & ACQUISITIONS

TABLE 155 INCYTE: PRODUCTS OFFERED

TABLE 156 INCYTE: KEY DEVELOPMENTS

TABLE 157 BAUSCH HEALTH COMPANIES INC.: PRODUCTS OFFERED

TABLE 158 KONINKLIJKE PHILIPS N.V.: PRODUCTS OFFERED

TABLE 159 DR. REDDY'S LABORATORIES LTD.: PRODUCTS OFFERED

TABLE 160 STRATA SKIN SCIENCES: PRODUCTS OFFERED

TABLE 161 STRATA SKIN SCIENCES: KEY DEVELOPMENTS

TABLE 162 CLINUVEL PHARMACEUTICALS LTD: PRODUCTS OFFERED

TABLE 163 ISSAR PHARMACEUTICALS PVT. LTD.: PRODUCTS OFFERED

TABLE 164 KERNEL MEDICAL EQUIPMENT CO., LTD.: PRODUCTS OFFERED

TABLE 165 LIGHTSOURCES: PRODUCTS OFFERED

TABLE 166 ROIVANT SCIENCES LTD.: PRODUCTS OFFERED

ページTOPに戻る

Table of Contents
List of Tables/Graphs

Summary

Vitiligo Treatment Market research report Forecast till 2030

Market Overview
The Vitiligo Treatment Market is projected to register a CAGR of 6.20% during the review period. Vitiligo is a persistent dermatological problem portrayed by skin depigmentation brought about by the failing or demise of the skin's color-delivering cells known as melanocytes. Accordingly, distinct white patches show up on the skin. The circumstances endure, making bigger areas of skin lose color. Treatment might further develop skin appearance yet doesn't fix the illness. The key factors that drive the worldwide vitiligo treatment market are the developing significance of tasteful allure and mindfulness and the rising commonness of vitiligo cases. the advancement of innovation proposing treatments for treating various difficulties brought about by the confusion, and the pervasiveness of speculations by government bodies in medical care foundation speeds up the market development.
Lately, there is a huge ascent in excellence cognizance among customers inferable from the developing mindfulness among shoppers about various style treatments, expanding per capita pay, and reception of computerized stages. As per the Global Society of Stylish Plastic Medical procedure (ISAPS), there was a 27.3% development in overall complete non-surgeries somewhere in the range between 2015 and 2019. Furthermore, as indicated by the American Culture of Plastic Specialists (ASPS), the quantity of negligibly intrusive tasteful systems saw about a 200% expansion during 2000-2017. Besides, around 15.9 million negligibly obtrusive restorative methods were acted in 2018, which was a 2% ascent in contrast with 2017. Subsequently, the rising geriatric populace additionally drives the interest in negligibly obtrusive restorative methodology.
Segment Overview
By Type, the vitiligo treatment market is divided into Segmental vitiligo and non-segmental vitiligo. By Treatment Type, the market is classified into Surgery, Therapy, and Medication.
By the End-User industry, the market is divided into Ambulatory Clinics, Hospitals, and Others.
Regional Analysis
North America ruled the worldwide vitiligo treatment market in 2021, owing to the presence of repayment exercises and the developing significance of tasteful allure likewise adding to regional market development.
As per the article distributed in the Diary of the European Foundation of Dermatology and Venereology (JEADV), the online-populace-based study exhibited that the commonness of vitiligo was 1.3% in Europe. Additionally, mechanical progressions in vitiligo treatment strategies are being taken on in the region because of the number of individuals languishing.
The vitiligo treatment market in Asia-Pacific is driven by an expansion in the number of innovative work exercises and developing interest in vitiligo treatment choices. For example, as indicated by the Indian Dermatology Online Diary (IDOJ), a cross-sectional review was led among 200 patients with vitiligo, the review expresses that 16.5% of people had segmental vitiligo, while 83.5% had non-segmental vitiligo. Besides, the ascent in the number of drives embraced by different public and confidential associations as acquisitions, joint efforts, administrative endorsements, and interests in this region is helping the market development.
Major Players
Incyte (US), Koninklijke Philips N.V. (Netherlands), Bausch Health Companies Inc. (Canada), Reddy's Laboratories Ltd. (India), STRATA Skin Sciences (US), Clinuvel Pharmaceuticals Ltd (Australia), Roivant Sciences Ltd. (Switzerland), ISSAR Pharmaceuticals Pvt. Ltd. (India), Kernel Medical Equipment Co., LTD. (China), and LightSource (US).
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

ページTOPに戻る

List of Tables/Graphs

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医療）の最新刊レポート

Market Research Future社の医療分野での最新刊レポート

本レポートと同じKEY WORD（）の最新刊レポート

本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問

Market Research Future社はどのような調査会社ですか?

マーケットリサーチフューチャー（Market Research Future）は世界市場を幅広く調査し、主要分野、地域、国レベルの調査レポートを出版しています。下記分野については、分野毎に専... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

白斑治療薬の2030年までの市場予測

サマリー

目次

図表リスト

Summary

Table of Contents

List of Tables/Graphs

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（医療）の最新刊レポート

Market Research Future社の医療分野での最新刊レポート

本レポートと同じKEY WORD（）の最新刊レポート

よくあるご質問

Market Research Future社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?